Affinity Asset Advisors LLC decreased its position in Immatics (NASDAQ:IMTX – Free Report) by 14.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 300,000 shares of the company’s stock after selling 50,000 shares during the quarter. Affinity Asset Advisors LLC owned about 0.35% of Immatics worth $3,486,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Baker BROS. Advisors LP lifted its holdings in shares of Immatics by 10.4% during the first quarter. Baker BROS. Advisors LP now owns 6,443,398 shares of the company’s stock worth $67,720,000 after buying an additional 604,545 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Immatics by 13.3% during the 4th quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock worth $66,896,000 after purchasing an additional 747,772 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Immatics by 38.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock worth $33,899,000 after purchasing an additional 891,191 shares during the period. Vestal Point Capital LP acquired a new stake in shares of Immatics in the fourth quarter valued at approximately $22,113,000. Finally, RA Capital Management L.P. acquired a new stake in Immatics during the first quarter worth approximately $18,392,000. Institutional investors and hedge funds own 64.41% of the company’s stock.
Immatics Price Performance
IMTX stock opened at $11.68 on Wednesday. The company’s 50-day moving average price is $11.78 and its two-hundred day moving average price is $11.56. Immatics has a 12 month low of $7.15 and a 12 month high of $13.77.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Immatics in a report on Thursday, September 5th.
Check Out Our Latest Stock Analysis on Immatics
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Further Reading
- Five stocks we like better than Immatics
- Pros And Cons Of Monthly Dividend Stocks
- Is Rivian Stock a Bargain Buy With 60% Upside Potential?
- Why Are Stock Sectors Important to Successful Investing?
- 4 Catalysts Poised to Push Caterpillar Stock to Record Highs
- What Are Dividend Champions? How to Invest in the Champions
- Why Small-Cap Stocks Could Be Ready to Outperform After Rate Cuts
Want to see what other hedge funds are holding IMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immatics (NASDAQ:IMTX – Free Report).
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.